Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2025
0mins
Source: NASDAQ.COM
Investment Agreement: Tempest Therapeutics has entered a definitive agreement for a registered direct offering of 739,000 shares at $6.25 each, expected to raise approximately $4.6 million to support its strategic initiatives and working capital.
Stock Performance: Following the announcement, TPST's stock closed at $7.47, reflecting a decline of 15.88%, but saw a slight increase in after-hours trading.
Analyst Views on TPST
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
